United States — Food and Drug Administration & Revolution Medicines

United States — Food and Drug Administration: The United States — Food and Drug Administration is expediting the review of daraxonrasib and has allowed expanded access to the drug, indicating its critical role in bringing this new treatment to patients.

Revolution Medicines: Revolution Medicines developed daraxonrasib, the experimental drug that has shown significant promise in treating advanced pancreatic cancer, leading to increased attention and potential for market growth for the company.

United States — Food and Drug Administration: The FDA is reviewing a rolling NDA for daraxonrasib under a priority voucher program, which could expedite U.S. approval.

Revolution Medicines: Revolution Medicines is the developer of daraxonrasib; the EMA phased review and FDA submission progress are key regulatory milestones that could lead to market approval and significant revenue.

United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body that Revolution Medicines will seek approval from for its experimental pancreatic cancer drug, daraxonrasib.

Revolution Medicines: Revolution Medicines is the maker of daraxonrasib, an experimental pill showing promise for advanced pancreatic cancer, and plans to seek United States — Food and Drug Administration approval.